The Haiefa, Israel, and Miami, Florida–based company develops the Exablate Neuro system. It uses focused sound waves safely guided by MRI. The system provides tremor treatment to patients with medication-refractory essential tremor and Parkinson’s disease. Focused ultrasound has FDA approval to treat both sides of the body. The second treatment occurs at least nine months after the first side for eligible patients.
Humana’s coverage extends to ultrasound treatment for medication-refractory essential tremor.
“We are pleased that this positive decision will expand access to focused ultrasound for more commercial patients,” said Dee Kolanek, Insightec VP of market access and reimbursement. “We are grateful to top insurers like Humana for expanding coverage of this revolutionary outpatient treatment for essential tremor patients.”
Humana follows Cigna, Anthem, Aetna and Blue Cross Blue Shield to grant Insightec positive coverage decisions. Its treatment has Medicare coverage in all 50 states as well.
“This coverage decision demonstrates further momentum towards our goal of expanding access to this transformative treatment, and we thank Humana for being a part of this movement,” added Dr. Maurice R. Ferré, CEO and board chair at Insightec. “Now, more patients with essential tremor will have access to a treatment that helps them get back to living independently.”
